Crispr Therapeutics shares tumble after significant earnings miss
Thomas J. Shaw, President and CEO of Retractable Technologies Inc. (AMEX:RVP), recently acquired 8,000 shares of the company’s common stock, according to a regulatory filing. The shares were purchased at a weighted average price of $0.66 per share, totaling approximately $5,280. The purchase comes as InvestingPro analysis shows the company trading below its Fair Value, despite maintaining a strong balance sheet with more cash than debt. Following this transaction, Shaw directly owns 15,390,459 shares. Additionally, Shaw holds indirect control over 831,600 shares, with investment power over 500,000 of these shares as a trustee for a family member. The stock acquisition was executed under a pre-established Rule 10b5-1 trading plan adopted on August 22, 2024. While the company currently faces profitability challenges with negative earnings, InvestingPro data reveals a robust current ratio of 6.7, indicating strong short-term financial health. Subscribers can access 4 additional exclusive ProTips and comprehensive financial metrics for deeper analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.